t cells

Alemtuzumab is a humanized monoclonal antibody against CD52 an antigen found on the surface of normal and malignant lymphocytes.

Atezolizumab is an antibody inhibitor, a humanized monoclonal antibody, IgG1, which targets PD-L1 and blocks the interaction of PD-L1 with PD-1. Atezolizumab has antitumor activity and promotes T-cells to attack tumor cells.

Pembrolizumab (MK-3475) is a humanized monoclonal antibody inhibiting the PD-1 receptor and the first in the class of agents called the HER2 dimerization inhibitors that impairs the ability of HER2 to bind to other members of the HER family.

Nivolumab is a monoclonal antibody, a humanized IgG4 antibody to PD-1. Nivolumab has antitumor activity and is used in the treatment of melanoma, non-small cell lung cancer, renal cell carcinoma and others.

ABP-102 (CT P72) is a tetravalent IgG1-[L]-scFv bispecific t-cell adduct (BiTE) that acts as a CD3 modulator and selective HER2 modulator for the selective targeting of HER2 overexpressing tumors. ABP-102 showed cytotoxicity in HER2-overexpressing models of breast and gastric cancers, while significantly decreasing activity against HER2 low level cells, twice as effective as rununmotamab.

Eftilagimod alfa (IMP321), a recombinant LAG-3Ig fusion protein, binds to MHC class II and mediates the activation of antigen-presenting cells (APCs), which in turn activates CD8 T-cells. It is utilized in the research of metastatic melanoma and metastatic breast carcinoma [1].

Ivuxolimab, an OX40 (also known as CD134; TNFRSF4) agonist monoclonal antibody, targets a costimulatory receptor found on activated CD4+ and CD8+ T cells. It demonstrates antitumor properties and may exhibit immunostimulatory activity [1].

Englumafusp alfa (CD19-4-1BBL; RO7227166) is a fusion protein that combines a CD19-specific antibody domain with trimerized extracellular domains of human 4-1BBL, engineered to induce CD19-specific 4-1BB cross-linking on T and NK cell surfaces [1].

Vudalimab, a fully humanized bispecific monoclonal antibody, effectively inhibits both PD-1 and CTLA-4 immune checkpoint receptors. This dual action facilitates the selective activation of T-cells targeting tumors.

Elranatamab (PF-06863135) is a humanized bispecific antibody that targets BCMA (B-cell maturation antigen) on myeloma cells and CD3 on T cells. By targeting these molecules, Elranatamab activates T cells and directs them to induce a cytotoxic T cell response against myeloma cells. This compound is used in research for relapsed or refractory multiple myeloma.

Foralumab (NI-0401) is an orally available human anti-CD3 monoclonal antibody that downregulates NKG7 and increases TGFB1 and GIMAP7 expression in T cells from COVID-19 subjects for the study of COVID-19 infection.

Odronextamab, a fully human, hinge-stabilized IgG4-based bispecific antibody, targets CD3 receptors on T cells and CD20 receptors on B cells [1].

Vibecotamab (XmAb14045) is a potent bispecific antibody that targets CD123 and CD3, promoting T cell-mediated elimination of CD123-expressing cells. It exhibits antitumor properties and is used in studies on acute myeloid leukemia [1].

INBRX-105 is a recombinant humanized bispecific antibody that targets programmed death-ligand 1 (PD-L1) and 4-1BB (CD137), exhibiting potential checkpoint inhibition, immune stimulation, and anti-tumor activity. By binding to 4-1BB on activated T-lymphocytes and PD-L1 on tumor cells, INBRX-105 enhances T-cell co-stimulation and inhibits PD-L1-mediated T-cell suppression, potentially reducing tumor growth. It demonstrates anti-tumor efficacy and increased T-cell frequency in patients with solid tumors and in vivo. Molecular weight: 101.9 kD.

HPN328 is a humanized trispecific T-cell activating construct (TriTAC) that targets CD3 to engage T cells, targets HSA to extend its half-life, and targets DLL3 on tumor cells. It effectively induces T-cell-mediated cytotoxicity against DLL3-expressing small cell lung cancer (SCLC), leading to tumor regression and sustained antitumor immunity. Molecular weight: 53.06 kDa.

Regn7075 is an innovative first-in-class bispecific antibody (bsAb) designed to restore immune sensitivity in traditionally unresponsive tumors by connecting CD28+ T cells with tumor cells expressing EGFR. It enhances immune response and antitumor immunity. The molecular weight is 145.24 KD.

Cibisatamab is a T-cell bispecific antibody that acts as a T-cell splicer.Cibisatamab targets carcinoembryonic antigen (CEA) on cancer cells and CD3 on T-cells, and triggers T-cell killing when the CEA on the surface of the cancer cells ranges from intermediate to high levels.Cibisatamab may be used to study solid cancers such as colorectal cancer.

Epcoritamab (GEN3013) is a novel subcutaneous CD3xCD20 bispecific T-cell binding antibody that activates T-cells and directs them to kill malignant CD20(+) B-cells for the study of relapsed or refractory large B-cell lymphoma.

Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine composed of a humanized 14.18 anti-GD2 monoclonal antibody (mAb) linked to interleukin-2 (IL2). It exerts anti-tumor effects [1] by inducing antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity, targeting GD2-expressing tumor cells, and stimulating NK and T cells via IL2 receptors.

Ertumaxomab (Anti-Human CD22 Recombinant Antibody) is a bispecific antibody that targets both HER2 neu and CD3. It functions by activating Fcγ type I III receptors, which facilitates the formation of a tri-cell complex involving tumor cells, T cells, and accessory cells. This compound has been utilized in the research of breast cancer [1].

Emfizatamab (GNC-038) is a tetravalent antibody that activates CD3 and 4-1BB on T cells while targeting CD19 or PD-L1 on tumor cells, resulting in T-cell-mediated cytotoxicity against human leukemia and lymphoma cells.

Anti-Mouse CD40 Antibody (FGK4.5 FGK45) is a rat-derived IgG2a monoclonal antibody targeting mouse CD40, a type I transmembrane glycoprotein within the tumor necrosis factor receptor (TNFR) superfamily. CD40 functions as a costimulatory molecule, activating B cells, dendritic cells, monocytes, and other antigen-presenting cells (APC), thereby enhancing antitumor T cell responses.

Tepoditamab (MCLA-117) is a bispecific monoclonal antibody targeting CLEC12A on myeloid cells and CD3 on cytotoxic T cells. As a myeloid differentiation antigen, CLEC12A allows the compound to eliminate AML leukemia progenitor and stem cells through T cell-mediated proliferative lysis, making it valuable in acute myeloid leukemia (AML) research [1].

Mosunetuzumab (BCT-4465A) is a humanized antibody based on immunoglobulin G1 that targets CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used to study relapsed or refractory (R R) B-cell non-Hodgkin lymphoma (B-NHL) and refractory follicular lymphoma.